## Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGE Form 4											
FORM	4 UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION								PROVAL 3235-0287	
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er <b>STATEN</b> 5. Filed pur <sup>s</sup> Section 17(	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1040							burden hou response	Estimated average burden hours per response 0.5	
(Print or Type R	esponses)										
Morris Charles Q Symbol			Symbol	er Name and Ticker or Trading NOGEN INC [IMGN]				5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) C/O IMMUNOGEN, INC., 830 WINTER STREET			3. Date of Earliest Transaction (Month/Day/Year) 11/28/2014					(Check all applicable) <u> </u>			
			endment, Date Original nth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
WALTHAM								Person	lore than One Re	eporting	
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)	Execution any		Code (Instr. 8)	on(A) or Disposed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	11/28/2014 <u>(2)</u>			S	5,240	D	\$ 10.4 (1)	32,260	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: IMMUNOGEN INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
Director 10% Owner Officer	Other						
Morris Charles Q C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451	DO						
Signatures							
/s/ Craig Barrows, attorney in fact 12/02/2014							
**Signature of Reporting Person Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Weighted average price of shares sold.

The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation(2) arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person on August 5, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.